Early antiretroviral therapy in HIV-1-infected infants, 1996-2008: Treatment response and duration of first-line regimens: The European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord

AIDS

Volumn 25, Issue 18, 2011, Pages 2279-2287

  Judd, Ali ^a  

^a NONE

Author keywords

antiretroviral therapy; drug switching; Europe; infant

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; DIDANOSINE; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NELFINAVIR; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; CYTOMEGALOVIRUS INFECTION; DRUG SUBSTITUTION; ETHNICITY; EUROPE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INFANT; MAJOR CLINICAL STUDY; MALE; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; PREDICTION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCORING SYSTEM; SEX; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG THERAPY, COMBINATION; EUROPE; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INFANT; INFANT, NEWBORN; MALE; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 80855139564     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32834d614c     Document Type: Article

References (35)

1. World Health Organization. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: progress report 2010. Geneva: WHO Press; 2010.
2. Goetghebuer T, Haelterman E, Le Chenadec J, Dollfus C, Gibb D, Judd A, et al. Effect of early antiretroviral therapy on the risk of AIDS/death in HIV-infected infants. AIDS 2009; 23:597-604.
3. Prendergast A, Mphatswe W, Tudor-Williams G, Rakgotho M, Pillay V, Thobakgale C, et al. Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants. AIDS 2008; 22:1333-1343.
4. Chiappini E, Galli L, Tovo PA, Gabiano C, Gattinara GC, Guarino A, et al. Virologic, immunologic, and clinical benefits from early combined antiretroviral therapy in infants with perinatal HIV-1 infection. AIDS 2006; 20:207-215.
5. Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, et al. Early antiretroviral therapy and mortality among HIVinfected infants. N Engl J Med 2008; 359:2233-2244.
6. Luzuriaga K, Bryson Y, Krogstad P, Robinson J, Stechenberg B, Lamson M, et al. Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection. N Engl J Med 1997; 336:1343-1349. (Pubitemid 27208617)
7. World Health Organization. Antiretroviral therapy of HIV infection in infants and children: towards universal access. Recommendations for a public health approach-2010 revision. Geneva: WHO Press; 2010.
8. PENTA Steering Committee. PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection. HIV Med 2009; 10:591-613.
9. Van der Linden D, Hainaut M, Goetghebuer T, Haelterman E, Schmitz V, Maes P, et al. Effectiveness of early initiation of protease inhibitor-sparing antiretroviral regimen in human immunodeficiency virus-1 vertically infected infants. Pediatr Infect Dis J 2007; 26:359-361. (Pubitemid 46596667)
10. Zanchetta M, Anselmi A, Vendrame D, Rampon O, Giaquinto C, Mazza A, et al. Early therapy in HIV-1-infected children: effect on HIV-1 dynamics and HIV-1-specific immune response. Antivir Ther 2008; 13:47-55. (Pubitemid 351541673)
11. Aboulker JP, Babiker A, Chaix ML, Compagnucci A, Darbyshire J, Debre M, et al. Highly active antiretroviral therapy started in infants under 3 months of age: 72-week follow-up for CD4 cell count, viral load and drug resistance outcome. AIDS 2004; 18:237-245. (Pubitemid 38253446)
12. Luzuriaga K, McManus M, Catalina M, Mayack S, Sharkey M, Stevenson M, et al. Early therapy of vertical human immunodeficiency virus type 1 (HIV-1) infection: control of viral replication and absence of persistent HIV-1-specific immune responses. J Virol 2000; 74:6984-6991. (Pubitemid 30470681)
13. Persaud D, Siberry GK, Ahonkhai A, Kajdas J, Monie D, Hutton N, et al. Continued production of drug-sensitive human immunodeficiency virus type 1 in children on combination antiretroviral therapy who have undetectable viral loads. J Virol 2004; 78:968-979. (Pubitemid 38067618)
14. Berk DR, Falkovitz-Halpern MS, Hill DW, Albin C, Arrieta A, Bork JM, et al. Temporal trends in early clinical manifestations of perinatal HIV infection in a population-based cohort. JAMA 2005; 293:2221-2231. (Pubitemid 40629188)
15. Walker AS, Doerholt K, Sharland M, Gibb DM. Response to highly active antiretroviral therapy varies with age: the UK and Ireland Collaborative HIV Paediatric Study. AIDS 2004; 18:1915-1924. (Pubitemid 39313207)
16. The PENPACT-1 (PENTA 9/PACTG 390) Study Team. First-line antiretroviral therapy with a protease inhibitor versus nonnucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial. Lancet Infect Dis 2011; 11:273-283.
17. Palumbo P, Violari A, Lindsey JC, Hughes M, Jean-Philippe P, Mofenson L, et al. NVP-vs LPV/r-based ART among HIVR infants in resource-limited settings: the IMPAACT P1060 trial [abstract 129LB]. In: 18th Conference on Retroviruses and Opportunistic Infections; 2011; Boston, Massachusetts, USA.
18. Moorthy A, Kuhn L, Coovadia A, Meyers T, Strehlau R, Sherman G, et al. Induction therapy with protease-inhibitors modifies the effect of nevirapine resistance on virologic response to nevirapine-based HAART in children. Clin Infect Dis 2011; 52:514-521.
19. Tudor-Williams G, Head S, Weigel R, Valerius NH, Riddell A, Lyall EGH. Baby cocktail! A protease-sparing 4 drug combination for symptomatic infants [abstract MoOrB1129]. In: The 14th International AIDS Conference; 2002; Barcelona, Spain.
20. Judd A, Doerholt K, Tookey PA, Sharland M, Riordan A, Menson E, et al. Morbidity, mortality, and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV infection during 1996-2006: planning for teenage and adult care. Clin Infect Dis 2007; 45:918-924. (Pubitemid 47580389)
21. Kjaer J, Ledergerber B. HIV cohort collaborations: proposal for harmonization of data exchange. Antivir Ther 2004; 9:631-633. (Pubitemid 39150221)
22. Wade AM, Ades AE. Age-related reference ranges: significance tests for models and confidence intervals for centiles. Stat Med 1994; 13:2359-2367. (Pubitemid 24354858)
23. Lee KJ, Lyall EGH, Walker AS, Sharland M, Judd A, Gibb DM, et al. Wide disparity in switch to second-line therapy in HIVinfected children in CHIPS [oral paper PL 2.4]. In: 8th International Congress on Drug Therapy in HIV Infection; 2006; Glasgow, UK.
24. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. JAmStat Assoc 1999; 94:496-509.
25. Paediatric European Network for Treatment of AIDS (PENTA). Response to planned treatment interruptions in HIV infection varies across childhood. AIDS 2010; 24:231-241.
26. Royston P. Multiple imputation of missing data. Stata J 2004; 4:227-241.
27. Greenland S, Finkle WD. A critical look at methods for handling missing covariates in epidemiologic regression analyses. Am J Epidemiol 1995; 142:1255-1264. (Pubitemid 26006424)
28. Violari A, Cotton M, Duong T, Jean-Philippe P, Panchia R, Josipovic D, et al. Virological and immunological responses in infants receiving a LPV/r-based regimen [poster abstract 843]. In: 17th Conference on Retroviruses and Opportunistic Infections; 2010; San Francisco, California, USA.
29. Reitz C, Coovadia A, Ko S, Meyers T, Strehlau R, Sherman G, et al. Initial response to protease-inhibitor-based antiretroviral therapy among children less than 2 years of age in South Africa: effect of cotreatment for tuberculosis. J Infect Dis 2010; 201:1121-1131.
30. Gibb DM, Newberry A, Klein N, de Rossi A, Grosch-Woerner I, Babiker A. Immune repopulation after HAART in previously untreated HIV-1-infected children. Paediatric European Network for Treatment of AIDS (PENTA) Steering Committee. Lancet 2000; 355:1331-1332. (Pubitemid 30199007)
31. The Italian Register for HIV Infection in Children. Rapid disease progression in HIV-1 perinatally infected children born to mothers receiving zidovudine monotherapy during pregnancy. AIDS 1999; 13:927-933.
32. Mphatswe W, Blanckenberg N, Tudor-Williams G, Prendergast A, Thobakgale C, Mkhwanazi N, et al. High frequency of rapid immunological progression in African infants infected in the era of perinatal HIV prophylaxis. AIDS 2007; 21:1253-1261. (Pubitemid 46883479)
33. Kempf DJ, King MS, Bernstein B, Cernohous P, Bauer E, Moseley J, et al. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis 2004; 189:51-60. (Pubitemid 38122329)
34. Kempf DJ, Isaacson JD, King MS, Brun SC, Sylte J, Richards B, et al. Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitorexperienced HIV-1-infected patients receiving lopinavir/ritonavir therapy. Antivir Ther 2002; 7:165-174. (Pubitemid 36427141)
35. Lee KJ, Dunn D, Porter K, Bansi RG, Hill T, Phillips AN, et al. Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy: multicentre cohort study. AIDS 2008; 22:1943-1950.